课题基金 / 基金详情

COVID 19 Supplemental work: HIGH THROUGHPUT BIOMARKER-BASED BIODOSIMETRY

COVID 19 Supplemental work: HIGH THROUGHPUT BIOMARKER-BASED BIODOSIMETRY
COVID 19 补充工作:基于高通量生物标志物的生物剂量测定
批准号:
10260009
负责人:
GEORGE SIGAL
金额:
$149.97万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-03-15 至 2021-05-10

项目摘要

项目成果

GEORGE SIGAL的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The company is working to develop serology assays for CoV-2 vaccine studies. The project leverages experience in developing and manufacturing high-throughput serology assays, and addresses the need for high quality CoV-2 reagents and tests that can be reproducibly manufactured at large scale. They also propose a study – in collaboration with Kaiser Permanente - to evaluate measurement of antibodies in saliva to assess immunity to SARS-CoV-2.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
HIGH THROUGHPUT BIOMARKER-BASED BIODOSIMETRY
  • 批准号:
    10382187
  • 项目类别:
  • 资助金额:
    $11.29万
  • 财政年份:
    2017
  • 负责人:
    GEORGE SIGAL
  • 依托单位:
HIGH THROUGHPUT BIOMARKER-BASED BIODOSIMETRY
  • 批准号:
    9915374
  • 项目类别:
  • 资助金额:
    $73.07万
  • 财政年份:
    2017
  • 负责人:
    GEORGE SIGAL
  • 依托单位:
海外基金